← Back to Screener
Eloxx Pharmaceuticals, Inc. Common Stock (ELOX)
Price$11.00
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-87.99%
Price vs S&P 500 (4W)457.83%
VGM Score23.29
Market Capitalization$488,573
All Metrics
Book Value / Share (Quarterly)$0.84
P/TBV (Annual)6.47x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)329.96%
Cash Flow / Share (Quarterly)$-1.31
Price vs S&P 500 (YTD)-46.26%
Net Profit Margin (TTM)-3862.50%
EPS (TTM)$-7.06
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-7.06
EPS (Annual)$-0.49
ROI (Annual)-194.09%
Net Profit Margin (5Y Avg)-8945.39%
Cash / Share (Quarterly)$1.25
ROA (Last FY)-113.76%
EBITD / Share (TTM)$-0.08
ROE (5Y Avg)-197.18%
Operating Margin (TTM)-4412.50%
Cash Flow / Share (Annual)$-1.32
P/B Ratio0.27x
P/B Ratio (Quarterly)12.91x
Net Income / Employee (Annual)$-599,500
EV / Revenue (TTM)-36.72x
Net Interest Coverage (TTM)-5.51x
ROA (TTM)-44.15%
EPS Incl Extra (Annual)$-0.49
Current Ratio (Annual)0.31x
Quick Ratio (Quarterly)0.45x
3-Month Avg Trading Volume0.01M
52-Week Price Return-78.70%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.66
P/S Ratio (Annual)0.08x
Asset Turnover (Annual)2.14x
52-Week High$11.60
Operating Margin (5Y Avg)-9696.34%
EPS Excl Extra (Annual)$-0.49
Tangible BV CAGR (5Y)-6.55%
26-Week Price Return-87.06%
Quick Ratio (Annual)0.28x
13-Week Price Return-75.37%
Total Debt / Equity (Annual)0.54x
Current Ratio (Quarterly)0.53x
Enterprise Value$-5.87M
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)76.53%
Revenue / Employee (Annual)$635,900
Pretax Margin (Annual)-49.43%
Cash / Share (Annual)$1.00
Net Income / Employee (TTM)$-375,400
ROE (Last FY)-298.10%
Net Interest Coverage (Annual)-624.67x
EPS Basic Excl Extra (Annual)$-0.49
Receivables Turnover (TTM)4.00x
Total Debt / Equity (Quarterly)6.76x
EPS Incl Extra (TTM)$-7.06
ROI (TTM)-150.95%
P/S Ratio (TTM)3.05x
Pretax Margin (5Y Avg)-9115.39%
Revenue / Share (Annual)$1.69
Tangible BV / Share (Annual)$2.59
Price vs S&P 500 (52W)-81.38%
Year-to-Date Return-36.81%
5-Day Price Return10.00%
EPS Normalized (Annual)$-0.49
ROA (5Y Avg)-306.82%
Net Profit Margin (Annual)-49.43%
Month-to-Date Return170.27%
Cash Flow / Share (TTM)$-8.79
EBITD / Share (Annual)$-0.41
Operating Margin (Annual)-39.20%
LT Debt / Equity (Annual)0.54x
ROI (5Y Avg)-132.25%
LT Debt / Equity (Quarterly)6.14x
EPS Basic Excl Extra (TTM)$-7.06
P/TBV (Quarterly)4.44x
P/B Ratio (Annual)2.72x
Pretax Margin (TTM)-3862.50%
Book Value / Share (Annual)$10.33
Price vs S&P 500 (13W)-76.16%
Beta3.36x
Revenue / Share (TTM)$0.00
ROE (TTM)-256.75%
52-Week Low$0.00
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Jun 2024
Jul 2024
Aug 2024
Sep 2024
4.29
4.29
4.29
4.29
Industry Peers — Biological Products(179)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ELOXEloxx Pharmaceuticals, Inc. Common Stock | — | — | D | $11.00 |
| AMGNAmgen Inc | C | C | C | $354.06 |
| GILDGilead Sciences Inc | C | B | C | $125.87 |
| ARGXargenx SE American Depositary Shares | D | A | B | $898.94 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $199.96 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $89.54 |
| MRNAModerna, Inc. Common Stock | C | B | C | $49.64 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $162.71 |
| EXELExelixis Inc | C | B | B | $53.50 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $321.55 |
About
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.